Loading news...
Carlsmed (NASDAQ: CARL - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings. Valuation and Earnings This table compares Carlsmed and Profusa"s
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024
Carlsmed's (NASDAQ: CARL - Get Free Report) lock-up period will end on Monday, January 19th. Carlsmed had issued 6,700,000 shares in its initial public offering on July 23rd. The total size of the offering was $100,500,000 based on an initial share price of $15.00. After the end of the company's lock-up period, restrictions preventing major shareholders
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery.
CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings.
Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop
CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am ET in New York, NY. During the conference, Carlsmed Management will be hosting 1x1 investor meetings.
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance.
CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to the Russell 2000® Index. This was part of the planned additions of select companies to this Index that had their IPO in the third quarter of 2025.
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company's aprevo® personalized interbody implants.
Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo® cervical procedure on July 14, 2025 by Joseph Osorio, MD, PhD, Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, CA.
Carlsmed's IPO debut is steady, with shares trading near the offering price, reflecting investor caution on its one-product, loss-making business model. Despite doubling sales and manageable cash burn, Carlsmed's valuation at 5–6x annualized sales appears reasonable given rapid revenue growth and a strong cash position. Key risks include heavy reliance on a single product, regulatory uncertainties, and competitive threats, making the investment thesis a high-risk, high-reward proposition.
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial price to the public of $15.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “CARL” on July 23, 2025. The offering is expected to close on July 24, 2025, su.